[Current therapeutic indications of thalidomide and lenalidomide]

Area of Science:

• Pharmacology
• Immunology
• Oncology

Background:

• Thalidomide, a synthetic glutamic acid derivative, was initially marketed as a safe sedative in 1956.
• It was withdrawn due to severe teratogenic effects, causing birth defects.
• Despite its history, thalidomide has found renewed therapeutic applications.

Purpose of the Study:

• To review the history, pharmacology, mechanism of action, clinical applications, and side effects of thalidomide.
• To discuss the development and limited clinical experience of new thalidomide analogues.
• To provide a comprehensive overview of thalidomide's complex medical journey.

Main Methods:

• Literature review of historical data, pharmacological studies, and clinical trials.
• Analysis of regulatory approvals and therapeutic indications.
• Examination of adverse event profiles and emerging analogues.

Main Results:

• Thalidomide's efficacy is established in treating erythema nodosum leprosum and multiple myeloma.
• It demonstrates effectiveness in various dermatological and immune-related conditions.
• New analogues are under development, but clinical data remains limited.

Conclusions:

• Thalidomide has evolved from a withdrawn sedative to a valuable therapeutic agent.
• Its use requires careful consideration of benefits versus risks, particularly regarding teratogenicity.
• Further research into thalidomide analogues may expand treatment options.